Aristotle and the Neoclassical Tradition: The Shifting Ground of ComplementarityWORLAND, S. T.History of Political Economy Durham, N.C. 1984, Vol 16, Num 1, pp 107-134Article

Inducible overexpression, purification, and active site mapping of DNA topoimerase II from the yeast Saccharomyces cerevisiaeWORLAND, S. T; WANG, J. C.The Journal of biological chemistry (Print). 1989, Vol 264, Num 8, pp 4412-4416, issn 0021-9258Article

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitorsDRAGOVICH, P. S; RU ZHOU; MEADOR, J. W et al.Bioorganic & medicinal chemistry letters (Print). 2000, Vol 10, Num 1, pp 45-48, issn 0960-894XArticle

Labeling quinone-binding sites in photosynthetic reaction centers: a 38-kilodalton protein associated with the acceptor side of photosystem IIWORLAND, S. T; YAMAGISHI, A; ISAACS, S et al.Proceedings of the National Academy of Sciences of the United States of America. 1987, Vol 84, Num 7, pp 1774-1778, issn 0027-8424Article

Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitorZALMAN, L. S; BROTHERS, M. A; DRAGOVICH, P. S et al.Antimicrobial agents and chemotherapy. 2000, Vol 44, Num 5, pp 1236-1241, issn 0066-4804Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; TIKHE, J et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2819-2834, issn 0022-2623Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P₁ lactam moieties as L-glutamine replacementsDRAGOVICH, P. S; PRINS, T. J; BURKE, B. J et al.Journal of medicinal chemistry (Print). 1999, Vol 42, Num 7, pp 1213-1224, issn 0022-2623Article

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C proteasePATICK, A. K; BINFORD, S. L; FUHRMAN, S. A et al.Antimicrobial agents and chemotherapy. 1999, Vol 43, Num 10, pp 2444-2450, issn 0066-4804Article

Nucleotide binding by the HIV-1 integrase protein in vitroLIPFORD, J. R; WORLAND, S. T; FARNET, C. M et al.Journal of acquired immune deficiency syndromes. 1994, Vol 7, Num 12, pp 1215-1223, issn 0894-9255Article

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acidsDRAGOVICH, P. S; WEBBER, S. E; BROWN, E. L et al.Bioorganic & medicinal chemistry letters (Print). 1999, Vol 9, Num 15, pp 2189-2194, issn 0960-894XArticle

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimeticsDRAGOVICH, P. S; PRINS, T. J; ZHOU, R et al.Journal of medicinal chemistry (Print). 1999, Vol 42, Num 7, pp 1203-1212, issn 0022-2623Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; LITTLEFIELD, E. S et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2806-2818, issn 0022-2623Article

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease : Design, synthesis, biological evaluation, and cocrystal structure solution of P₁ glutamine isosteric replacementsWEBBER, S. E; OKANO, K; MEADOR, J. W et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2786-2805, issn 0022-2623Article

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C proteaseWEBBER, S. E; TIKHE, J; BROWN, E. L et al.Journal of medicinal chemistry (Print). 1996, Vol 39, Num 26, pp 5072-5082, issn 0022-2623Article

Isolation and amino-terminal sequences of subunits from the photosynthetic reaction center of Rhodopseudomonas capsulataWORLAND, S. T; WILSON, K. J; HEARST, J. E et al.Biochimica et biophysica acta. 1984, Vol 767, Num 3, pp 651-654, issn 0006-3002Article